Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately. Mr. Loeb will oversee all legal matters for Sangamo and will report to the Chief Executive Officer.

"Gary brings dynamic experience in pharmaceutical compliance, legal operations, and executive leadership,” said Sandy Macrae, Sangamo's Chief Executive Officer. "We are pleased Gary is joining Sangamo and look forward to his contributions as Sangamo continues to grow as a clinical stage development company, and eventually into commercialization.”

Mr. Loeb has over 20 years of experience in biotechnology and pharmaceutical law, compliance, intellectual property, litigation, human resources, regulatory, and facilities. Before joining Sangamo, he served as General Counsel, Corporate Secretary, and Chief Compliance Officer at Achaogen, an anti-infectives company. At Achaogen, Mr. Loeb was a member of the Executive Team and the first full-time in-house attorney, where he built the legal and compliance teams. Before Achaogen, Mr. Loeb worked in roles of increasing responsibility at Counsyl, a genetic screening company, Amyris, Inc., and Genentech.

Mr. Loeb received his B.S. and B.A. degrees from Stanford University and his J.D. from Columbia Law School.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com

Forward-Looking Statements

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's anticipated growth as a clinical stage development company and into commercialization. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the costly and inherently uncertain research and development process; the completion of clinical trials of Sangamo’s product candidates; Sangamo’s limited experience in conducting later stage clinical trials and the potential inability of Sangamo and its partners to advance Sangamo’s product candidates into registrational studies; Sangamo's reliance on third-parties to meet their clinical and manufacturing obligations; Sangamo’s ability to maintain strategic partnerships; Sangamo’s ability to manage its growth; Sangamo’s current lack of infrastructure or capability to manufacture, market and sell therapeutic products on a commercial scale; and the potential for technological developments by Sangamo's competitors that will obviate Sangamo's gene therapy technology. Further, there can be no assurance that the necessary regulatory approvals will be obtained for Sangamo’s product candidates or that Sangamo and its partners will be able to develop commercially viable product candidates. Actual results may differ from those projected in forward-looking statements due to these and other risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 as filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190731005868/en/